摘要
目的筛选出与Hep-2细胞株特异结合的短肽,作为喉癌靶向治疗的载体。方法采用ELISA法鉴定噬菌体与Hep-2细胞的结合活性;通过免疫荧光、流式细胞学检测技术检测鉴定F2噬菌体阳性克隆与喉癌细胞结合的特异性。结果ELISA分析鉴定显示5个阳性克隆能与Hep-2细胞特异结合,其中F2噬菌体克隆对喉癌细胞的结合靶向性明显高于人正常喉黏膜上皮细胞;用流式细胞仪进行定量分析,其结果显示F2与Hep-2的结合率为(53.77±4.2)%,显著高于与人正常喉黏膜上皮细胞的结合率[(12.58±3.2)%,P<0.05];免疫荧光显色证实,FITC-F2能特异性地与喉癌细胞结合。结论 F2能与喉癌细胞特异性的结合,其可能成为喉癌靶向治疗的载体。
Objective To screen the polypeptides specifically bound to laryngeal squamous cell carcinoma line（Hep-2） as a potential therapeutic vector targeting laryngeal squamous cell carcinoma. Methods The affinity of phage clones to Hep-2 was detected by en- zymedinked immunosorbent assay（ELISA）. The positive phage clones（ F2/F9 ）specifically bound to Hep-2 were identified by flow cy- tometry and immunofluorescenee detection. Results Five positive clones were bound to Hep-2 cells by enzyme-linked immunosorbent assay（ELISA）. The affinity of positive phage clones（F2） to Hep-2 was significantly higher than that to normal laryngeal cells. By flow cytometry, the binding rate of F2 to Hep-2 cells was （53.77 ± 4.2 ）%, statistically higher than that to normal laryngeal cells（ 12.58± 3.2 ） % （ P 〈 0.05 ）. The immunofluorescence results showed that FITC-F2 was specifically bound to Hep-2. Conclusion F2 can spe- cifically bind to Hep-2 cells, and could be a potential vector for the target therapy of laryngeal squamous cell carcinoma.
出处
《山西医科大学学报》
CAS
2013年第4期275-278,325,326,共6页
Journal of Shanxi Medical University
基金
四川省教育厅基金资助项目(12ZA054)
川北医学院科研发展计划资助项目(CBY11-A-ZP08)
关键词
喉鳞癌
HEP-2细胞
短肽
靶向治疗
laryngeal squamous cell carcinoma
Hep-2 cell
peptide
target therapy
